Vascular Disease

6

Review clinical trials related to Vascular Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)

People living with HIV (PLHIV) live longer because of modern HIV medicines, but even with these treatments, their bodies are more inflamed. Long term inflammation increases the risk of heart disease, chronic pain, lung disease, dementia, arthritis, and other infections. Because some anti-inflammatory medicines can cause serious side effects, interact with HIV drugs, or be costly, safer and more affordable treatment options are needed. Genistein is a natural compound found in soy foods. It is considered safe and has been shown to reduce inflammation and improve blood vessel health. This study will test whether genistein can lower inflammation in the blood, improve blood vessel health, and reduce pain in PLHIV.

Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUpdated: Aug 25, 2026Locations: 1
Eligibility criteria

age: 19-80 [+5]

if HIV positive: detectable viral load or CD4<350 [+20]

Status: Recruiting

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.

Participants needed: 1,500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: W.L.Gore & AssociatesUpdated: Aug 19, 2026Locations: 37Duration: 10 Years
Eligibility criteria

Patient or legally authorized representative (LAR) provides written authorizatio... [+3]

Patient who is, at the time of consent, unlikely to be available for standard of... [+3]

Status: Not yet recruiting

MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eyes and blood vessels; thus targeting proinflammatory lipid mediators called leukotrienes may represent a promising therapy for diabetes complications. This clinical trial seeks to investigate whether montelukast, a leukotriene antagonist, improves kidney, eye and vascular function in adult participants with type 2 diabetes and kidney disease.

Participants needed: 110
Trial details
Phase: Phase 4Age: 18-80Biological sex: AllType: InterventionalSponsor: University of Colorado, DenverUpdated: Jul 6, 2026Locations: 1
Eligibility criteria

Diabetes type 2 [+7]

Type 1 diabetes [+7]

Status: Not yet recruiting

Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes

Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.

Participants needed: 3,000
Trial details
Biological sex: AllType: InterventionalSponsor: Gravity Medical Technology, INCUpdated: Jan 13, 2026
Eligibility criteria

Subject has experienced an Acute Ischemic Stroke due to large intracranial vesse... [+2]

Concurrent participation in another mechanical neurothrombectomy device trial or...

Status: Recruiting

Studies of Neuregulin/ERBB Signaling in Human Heart

This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.

Participants needed: 80
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Douglas B. SawyerUpdated: Apr 3, 2025Locations: 1
Eligibility criteria

Clinical diagnosis of severe coronary artery disease scheduled to undergo corona...

less than 18 years of age [+8]

Status: Recruiting

A Preventive, Multidisciplinary Primary Care Intervention Organized Around a Therapeutic Garden: Acceptability to Patients Suffering from Cardio-neurovascular Pathology and to Those Involved in the Action.

A preventive, multidisciplinary primary care intervention organized around a therapeutic garden: Acceptability to patients suffering from cardio-neurovascular pathology and to those involved in the action.

Participants needed: 157
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Assistance Publique Hopitaux De MarseilleUpdated: Oct 17, 2024Locations: 1
Eligibility criteria

age > 18 years old; [+3]

heart failure based on CNAM medical criteria (ALD n°5) stage III and IV accordin... [+5]